Plavix Could Face Rival Prasugrel In Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
Combined Lilly/Daiichi sales force stands ready to support antiplatelet drug’s launch when approval comes, Lilly head of cardiovascular research tells “The Pink Sheet” DAILY.
You may also be interested in...
Lilly’s Prasugrel Could Gain FDA Approval In June
Anti-clotting agent was granted a six-month priority review by FDA.
Lilly’s Prasugrel Could Gain FDA Approval In June
Anti-clotting agent was granted a six-month priority review by FDA.
Lilly’s Prasugrel Superior To Bristol’s Plavix In Reducing CV Events In Pivotal TRITON Trial
Efficacy tempered by an increase in non-CABG bleeding compared to clopidogrel.